Blog & Press

Neoadjuvant chemotherapy (NAT) is commonly used before surgery in women with triple-negative and HER2-positive breast cancers. Multiple studies have established that tamoxifen therapy consistently

A variety of thresholds and time frames have been suggested for estimating risk of developing breast cancer as a guide to interventions including supplemental screening and risk-reducing medications:

NCCN Update: Incorporating 5-Year Risk The March 2026 NCCN breast screening guidelines now include guidance to “consider” supplemental MRI screening for women with a 5-year Gail model risk